Novavax delays US trial start of Covid-19 vaccine to November
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
[NEW YORK] Novavax on Tuesday delayed the timeline for beginning a late-stage US trial of its experimental coronavirus vaccine by roughly one month.
The company said it would begin the trial by the end of November. It previously expected to start this month.
Novavax said it also expects interim data from an ongoing late-stage UK trial of its coronavirus vaccine in the first quarter of next year.
The company said it had expanded its enrollment target in the UK trial to 15,000 volunteers from 10,000. It expects this could help assess safety and effectiveness of the vaccine in a shorter time period.
REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
Singaporeans can now buy record amount of yen per Singdollar
Beijing’s calculated silence on the Iran war
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
StarHub hands Ensign InfoSecurity control back to Temasek in S$115 million deal, books S$200 million gain
